# Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

> **NCT01959490** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Stage II Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **BIOLOGICAL:** Pertuzumab
- **DRUG:** docetaxel
- **DRUG:** carboplatin
- **DRUG:** doxorubicin
- **DRUG:** cyclophosphamide
- **DRUG:** paclitaxel
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01959490
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-24
- **Primary completion:** 2016-11-11
- **Final completion:** 2017-03-29
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01959490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01959490, "Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01959490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*